Deadline to Lead in Securities Fraud Lawsuit against DexCom, Inc. (DXCM) is October 21, 2024 – Contact Kaplan Fox & Kilsheimer LLP

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. due to significant stock price decline following the company's lowered sales guidance and operational issues [1][3] Financial Performance - On July 25, 2024, DexCom lowered its full year 2024 sales guidance to between $4 billion and $4.05 billion, a reduction of approximately $300 million from the previous guidance of $4.20 billion to $4.35 billion [2] - The company reported a "new patient shortfall" of 70,000 patients attributed to a "sales force disruption" and loss of market share in the Durable Medical Equipment channel [2] Stock Market Reaction - Following the announcement of the lowered guidance, DexCom's stock price fell by $43.85 per share, over 40%, closing at $64 per share on July 26, 2024 [3] Allegations in Lawsuit - The lawsuit alleges that during the class period, DexCom provided overly positive statements while concealing material adverse facts about its salesforce capabilities, leading to artificially inflated stock prices [3]